Labcorp Holdings Inc. (LH) Operating Cash Flow CAGR:10.98%(TTM)
Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
Over longer horizons, Labcorp Holdings Inc.'s Operating Cash Flow CAGR averages 1.76% over 3 years and -10.11% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash Labcorp Holdings Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
LH Operating Cash Flow CAGR Chart
Labcorp Holdings Inc. (LH)
LH Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
LH Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $1.59B | $1.64B | +$54.70M | +3.45% | +3.45% |
| 2024 | $1.33B | $1.59B | +$258.10M | +19.44% | +19.44% |
| 2023 | $1.96B | $1.33B | $-628.20M | -32.12% | -32.12% |
| 2022 | $3.11B | $1.96B | $-1.15B | -37.10% | -37.10% |
| 2021 | $2.14B | $3.11B | +$974.30M | +45.63% | +45.63% |
| 2020 | $1.44B | $2.14B | +$690.60M | +47.80% | +47.80% |
| 2019 | $1.31B | $1.44B | +$139.30M | +10.67% | +10.67% |
| 2018 | $1.46B | $1.31B | $-154.00M | -10.55% | -10.55% |
| 2017 | $1.18B | $1.46B | +$283.50M | +24.11% | +24.11% |
| 2016 | $982.40M | $1.18B | +$193.50M | +19.70% | +19.70% |
| 2015 | $739.00M | $982.40M | +$243.40M | +32.94% | +32.94% |
| 2014 | $818.70M | $739.00M | $-79.70M | -9.73% | -9.73% |
| 2013 | $841.40M | $818.70M | $-22.70M | -2.70% | -2.70% |
| 2012 | $855.60M | $841.40M | $-14.20M | -1.66% | -1.66% |
| 2011 | $883.60M | $855.60M | $-28.00M | -3.17% | -3.17% |
| 2010 | $862.40M | $883.60M | +$21.20M | +2.46% | +2.46% |
| 2009 | $780.90M | $862.40M | +$81.50M | +10.44% | +10.44% |
| 2008 | $709.70M | $780.90M | +$71.20M | +10.03% | +10.03% |
| 2007 | $632.30M | $709.70M | +$77.40M | +12.24% | +12.24% |
| 2006 | $574.20M | $632.30M | +$58.10M | +10.12% | +10.12% |
| 2005 | $538.10M | $574.20M | +$36.10M | +6.71% | +6.71% |
| 2004 | $564.30M | $538.10M | $-26.20M | -4.64% | -4.64% |
| 2003 | $444.90M | $564.30M | +$119.40M | +26.84% | +26.84% |
| 2002 | $316.00M | $444.90M | +$128.90M | +40.79% | +40.79% |
| 2001 | $246.70M | $316.00M | +$69.30M | +28.09% | +28.09% |
| 2000 | $180.50M | $246.70M | +$66.20M | +36.68% | +36.68% |
| 1999 | $125.10M | $180.50M | +$55.40M | +44.28% | +44.28% |
| 1998 | $144.40M | $125.10M | $-19.30M | -13.37% | -13.37% |
| 1997 | $-186.80M | $144.40M | +$331.20M | N/A | N/A |
Quarterly Operating Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $191.50M | -68.8% | — |
| Q4 2025 | $614.20M | +58.6% | -21.0% |
| Q3 2025 | $387.20M | -37.6% | +39.6% |
| Q2 2025 | $620.60M | — | +10.6% |
| Q1 2025 | $18.50M | -97.6% | — |
| Q4 2024 | $777.20M | +180.3% | +34.1% |
| Q3 2024 | $277.30M | -50.6% | +0.7% |
| Q2 2024 | $561.10M | — | +64.5% |
| Q1 2024 | -$29.80M | — | — |
| Q4 2023 | $579.60M | +110.4% | -11.3% |
| Q3 2023 | $275.50M | -19.2% | -26.3% |
| Q2 2023 | $341.10M | +181.4% | -40.4% |
| Q1 2023 | $121.20M | -81.5% | -66.0% |
| Q4 2022 | $653.60M | +74.9% | -6.3% |
| Q3 2022 | $373.80M | -34.7% | -51.3% |
| Q2 2022 | $572.50M | +60.8% | +17.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Adam H. Schechter